DBV Technologies is the only company in the world whose products are designed to epicutaneously deliver on intact skin — via an epicutaneous patch — allergens for Epicutaneous Immunotherapy (EPIT) against food allergies or for allergy diagnosis. Using its proprietary patented delivery system VIASKIN®, DBV Technologies’ approach is to deliver biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. VIASKIN® is a non-invasive delivery system that utilizes electrostatic forces to present and deliver active compounds to the epidermis of the skin, without breaking the basement membrane (blood-skin barrier). As presented compounds, such as allergens, do not cross the blood-skin barrier, the risk of anaphylactic shock in allergic patients is dramatically reduced.
Company: | DBV Technologies | |
Headquarters Address: | Green Square - Bâtiment D 80/84 rue des Meuniers | |
Bagneaux 92220 | ||
France | ||
Main Telephone: | +33 (0)1 55 42 78 78 | |
Website: | ||
Ticker/ISIN: | DBV(BOURSE)/FR0010417345 | |
Type of Organization: | Public | |
IRPR | ||
Industry: | Biotechnology | |
Earnings Release Dates: | 1st Quarter: April 15, 2013 | |
3rd Quarter: October 15, 2013 | ||
Key Executives: | CEO: Pierre-Henri Benhamou | |
CFO: David Schilansky | ||
Co-Founder, CIO: Bertrand Dupont | ||
Public Relations | ||
Contact: | Ronald Trahan | |
Phone: | 5083594005 | |
Email: | ||
Investor Relations | ||
Contact: | NewCap IR | |
Phone: | +33 1 84 16 29 01 | |
Email: |